Compare Becton Dickinson and Co (BDX) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs SOLAI Limited — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while SOLAI Limited trades at $3.14 (market cap $14.09M). The key difference: Becton Dickinson and Co is far larger — about 2946.1× SOLAI Limited's market cap, and Becton Dickinson and Co pays a 2.79% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| BDX | SLAI | |
|---|---|---|
Market Cap | $41.51B | $14.09M |
Sector | Health | Technology |
52-Week High | $185.39 | $30.66 |
52-Week Low | $135.49 | $2.74 |
Enterprise Value | $57.97B | $13.72M |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
SLAI trades at $3.24, down 2.99% today, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include the acquisition of a 51% stake in NEURALAND and the launch of Solode Neo AI device. The stock faces NYSE listing standard concerns but shows improved revenue guidance for 2026.
The outlook remains challenged by persistent losses and regulatory risks, though recent acquisitions and product launches offer potential growth catalysts. Investors face significant execution risk amid negative profitability metrics, while technical indicators suggest near-term price support around $3 with resistance at $4.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
